Literature DB >> 2772465

Community-acquired pneumonia requiring hospitalization: 5-year prospective study.

T J Marrie1, H Durant, L Yates.   

Abstract

We studied all patients with community-acquired pneumonia who were admitted to our 800-bed adult acute care hospital from 1 November 1981 to 15 March 1987. The 719 patients had a mean age of 63.2 years; 18% were admitted from nursing homes, and 18% required ventilatory assistance as part of the therapy for pneumonia. Patients with nursing home-acquired pneumonia were significantly older; had a higher mortality (40% vs. 17%); were more likely to be admitted in January; were less likely to complain of cough, fever, anorexia, chills, headache, nausea, sore throat, myalgia, or arthralgia; and were more likely to be confused than those admitted from the community. Pneumonia of unknown etiology and aspiration pneumonia were more common and Mycoplasma pneumoniae infection less common among those with nursing home-acquired pneumonia. Streptococcus pneumoniae accounted for 58% of the 48 cases of bacteremia. None of the bacteremic patients received antibiotics before admission, compared with 34% of the nonbacteremic patients. Aerobic gram-negative rod bacteremia was not more frequent among nursing home patients than among those from the community. The overall mortality was 21% (8.5% for those less than 60 years of age and 28.6% for those greater than 60 years old). By multivariate analysis the following variables were significant predictors of mortality: number of lobes involved by the pneumonic process, number of antibiotics used to treat the pneumonia, age, admission from a nursing home, ventilatory support, and the number of complications that occurred while the patient was in the hospital.

Entities:  

Mesh:

Year:  1989        PMID: 2772465     DOI: 10.1093/clinids/11.4.586

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  126 in total

1.  Severity prediction rules in community acquired pneumonia: a validation study.

Authors:  W S Lim; S Lewis; J T Macfarlane
Journal:  Thorax       Date:  2000-03       Impact factor: 9.139

2.  Molecular detection of Mycoplasma pneumoniae in adults with community-acquired pneumonia requiring hospitalization.

Authors:  J W Dorigo-Zetsma; R P Verkooyen; H P van Helden; H van der Nat; J M van den Bosch
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

3.  BTS Guidelines for the Management of Community Acquired Pneumonia in Adults.

Authors: 
Journal:  Thorax       Date:  2001-12       Impact factor: 9.139

4.  Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America.

Authors:  J G Bartlett; S F Dowell; L A Mandell; T M File; D M Musher; M J Fine
Journal:  Clin Infect Dis       Date:  2000-09-07       Impact factor: 9.079

5.  Measuring symptomatic and functional recovery in patients with community-acquired pneumonia.

Authors:  J P Metlay; M J Fine; R Schulz; T J Marrie; C M Coley; W N Kapoor; D E Singer
Journal:  J Gen Intern Med       Date:  1997-07       Impact factor: 5.128

6.  Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study.

Authors:  W S Lim; M M van der Eerden; R Laing; W G Boersma; N Karalus; G I Town; S A Lewis; J T Macfarlane
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

7.  Reasons for choice of antibiotic for the empirical treatment of CAP by Canadian infectious disease physicians.

Authors:  J Pendergrast; T Marrie
Journal:  Can J Infect Dis       Date:  1999-09

8.  Q fever in Quebec (1989-93): Report of 14 cases.

Authors:  M Goyette; A Poirier; J Bouchard; E Morrier
Journal:  Can J Infect Dis       Date:  1994-05

9.  Antimicrobial treatment of community acquired pneumonia in adults: A conference report.

Authors:  L Mandell; M Niederman
Journal:  Can J Infect Dis       Date:  1993-01

Review 10.  Drug treatment of pneumonia in the elderly: efficacy and costs.

Authors:  E Saltiel; S Weingarten
Journal:  Pharmacoeconomics       Date:  1993-04       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.